Rate of brain atrophy in benign vs early multiple sclerosis

Archives of Neurology

Volumn 66, Issue 2, 2009, Pages 234-237

  Gauthier, Susan A ^a,c,d   Berger, Annika M ^b   Liptak, Zsuzsanna ^b   Duan, Yang ^b   Egorova, Svetlana ^b   Buckle, Guy J ^a   Glanz, Bonnie I ^a   Khoury, Samia J ^a   Bakshi, Rohit ^b   Weiner, Howard L ^a   Guttmann, Charles R G ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Department of Radiology ^*  (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; METHYLPREDNISOLONE;

ADULT; ARTICLE; BRAIN ATROPHY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADULT; AGE DISTRIBUTION; AGE OF ONSET; AGED; ATROPHY; BRAIN; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 60549086125     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2008.567     Document Type: Article

References (26)

1. Ramsaransing GS, De Keyser J. Benign course in multiple sclerosis: a review. Acta Neurol Scand. 2006;113(6):359-369.
2. Hohol MJ, Guttmann CR, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol. 1997: 54(8):1018-1025.
3. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L; Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology. 1999;53(8):1698-1704.
4. Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain. 2002;125(pt 8):1676-1695.
5. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5(2):158-170.
6. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59(9):1412-1420.
7. Gauthier SA, Glanz BI, Mandel M, Weiner HL. A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev. 2006;5(8):532-536.
8. Wei X, Warfield SK, Zou KH, et al. Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging. 2002;15(2):203-209.
9. De Stefano N, Battaglini M, Stromillo ML, et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain. 2006;129(pt 8):2008-2016.
10. Filippi M, lannucci G, Tortorella C, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology. 1999;52(3): 588-594.
11. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;63(6):736-742.
12. Brass SD, Narayanan S, Antel JP, Lapierre Y, Collins L, Arnold DL. Axonal damage in multiple sclerosis patients with high versus low expanded disability status scale score. Can J Neurol Sci. 2004;31(2):225-228.
13. Horsfield MA, Lai M, Webb SL, et al. Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance. Magn Reson Med. 1996;36(3):393-400.
14. Droogan AG, Clark CA, Werring DJ, Barker GJ, McDonald WI, Miller DH. Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging. Magn Reson Imaging. 1999;17(5):653-661.
15. Ceccarelli A, Rocca MA, Pagani E, et al. The topographical distribution of tissue injury in benign MS: a 3T multiparametric MRI study. Neuroimage. 2008;39 (4):1499-1509.
16. Strasser-Fuchs S, Enzinger C, Ropele S, Wallner M, Fazekas F. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox? Mult Scler. 2008;14(2):205-211.
17. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. Alongitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158-163.
18. Tintore M, Rovira A, Río J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology. 2006;67(6):968-972.
19. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol. 2006;60(2):236-242.
20. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol. 2004:56(2):303-306.
21. Hawkins SA, McDonnell GV. Benign multiple sclerosis? clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry. 1999;67(2):148-152.
22. Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology. 2007;68(7):496-500.
23. Amato MP, Zipoli V, Goretti B, et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol. 2006;253(8):1054-1059.
24. Christodoulou C, Krupp LB, Liang Z, et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology. 2003: 60(11):1793-1798.
25. Lazeron RH, de Sonneville LM, Scheltens P, Polman CH, Barkhof F. Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. Mult Scler. 2006;12(6):760-768.
26. Ramsaransing GS, De Keyser J. Predictive value of clinical characteristics for "benign" multiple sclerosis. Eur J Neurol. 2007;14(8):885-889.